Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | GNA15 | P30679 | 1/20 | 0.46 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5681744 | 0.82 | PTPN1 (0.56) | ALDH1A1SMN1; SMN2HTTKDM4EFFAR1 | |
| SCHEMBL4019172 | 0.81 | MAPK14 (0.67) | SMN1; SMN2HTTMAPK14MEN1KMT2A | |
| SCHEMBL4613350 | 0.81 | SMN1; SMN2 (0.50) | ALDH1A1SMN1; SMN2HTTKDM4EFFAR1 | |
| SCHEMBL14309140 | 0.80 | CYP1A2 (0.56) | ALDH1A1SMN1; SMN2HTTKDM4EFFAR1 | |
| SCHEMBL5201809 | 0.80 | FFAR1 (0.49) | PTGESFFAR1GNA15PTGER3FFAR4 | |
| Hydrochloric Acid SCHEMBL4015668 | 0.79 | CYP1A2 (0.55) | ALDH1A1SMN1; SMN2HTTKDM4EFFAR1 | |
| SCHEMBL5205144 | 0.76 | CACNA1B (0.44) | PTGESHTTFFAR1GNA15PTGER3 | |
| SCHEMBL5681738 | 0.75 | FFAR1 (0.74) | FFAR1GNA15PTGER3FFAR4TDP1 | |
| SCHEMBL8773482 | 0.74 | MEN1 (0.69) | ALDH1A1HTTTDP1MEN1KMT2A | |
| SCHEMBL5204934 | 0.73 | PTGES (0.39) | PTGESHTTFFAR1GNA15PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482487-B2 | Phenylaminoethanol derivatives as β2 receptor agonists | PFIZER INC (US) | 2009-01-27 | — | — | US | disclosed |
| US-20070264262-A1 | Phenylaminoethanol Derivates as Beta 2 Receptor Agonists | BROWN ALAN D | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070264262-A1 | Phenylaminoethanol Derivates as Beta 2 Receptor Agonists | ADRB2, ADRB1, ADRA2C | PTGES 98/4885ALDH1A1 356/4885SMN1; SMN2 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.